Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

41.20 USD -0.36 (-0.87%)
Streaming Delayed Price Updated: 12:04 PM EDT, Apr 12, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 298,654
Open 41.37
Bid (Size) 41.19 (2)
Ask (Size) 41.25 (1)
Prev. Close 41.56
Today's Range 40.53 - 41.78
52wk Range 25.49 - 58.47
Shares Outstanding 55,941,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The NEJM publishes phase 3 PEGASUS study results comparing pegcetacoplan to eculizumab for PNH
Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in haemoglobin levels... 
From PR Newswire
Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH
From GlobeNewswire News Releases

Performance

YTD
-24.53%
-24.53%
1 Month
-11.70%
-11.70%
3 Month
-26.79%
-26.79%
6 Month
+16.42%
+16.42%
1 Year
+46.57%
+46.57%

More News

Read More
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy
From GlobeNewswire News Releases
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Apellis Provides Update on APL-9 for Severe COVID-19
From GlobeNewswire News Releases
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
From GlobeNewswire News Releases
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021
From GlobeNewswire News Releases
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
From GlobeNewswire News Releases
Apellis Pharmaceuticals to Host Investor Event on Geographic Atrophy on January 28, 2021
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.